ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
36.28
-1.60%
US Tech 100
18,068.80
-1.73%
S&P 500
5,446.68
-1.37%
US Dollar vs CAD
1.38788
-0.01%
Bitcoin
64,398.42
-1.46%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NYSE
  6. Johnson and Johnson (JNJ)

  7. Johnson and Johnson (JNJ) News

JNJ

Johnson and Johnson (JNJ)

Johnson and Johnson
Date:
Sort by:
 Showing the most relevant articles for your search:NYSE:JNJ
DateTimeSourceHeadlineSymbolCompany
07/30/20248:06PMEdgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNYSE:JNJJohnson and Johnson
07/30/20245:42PMPR Newswire (US)DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet regimen approved in the U.S. for patients with newly diagnosed multiple myeloma who are transplant-eligibleNYSE:JNJJohnson and Johnson
07/30/20245:00AMIH Market NewsToyota Reports Another Global Production Decline, Delta Sues CrowdStrike, Meta Launches AI Studio for Custom ChatbotsNYSE:JNJJohnson and Johnson
07/29/20243:00PMBusiness WireJohnson & Johnson to Participate in the 2024 Wells Fargo Healthcare ConferenceNYSE:JNJJohnson and Johnson
07/26/20248:38AMBusiness WireCourts, Congress Likely to Stand in Way of J&J’s Third Texas Two-Step PlanNYSE:JNJJohnson and Johnson
07/26/20248:05AMBusiness WireFINAL DEADLINE: Ovarian Cancer Victims Have Until 5pm ET Today to Vote on Approximately $8 Billion J&J Talc Compensation PlanNYSE:JNJJohnson and Johnson
07/26/20245:07AMIH Market NewsAlphabet Unveils AlphaProof and AlphaGeometry 2; OpenAI Tests SearchGPT; Apple Loses Market Share in ChinaNYSE:JNJJohnson and Johnson
07/25/20243:02PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:JNJJohnson and Johnson
07/23/20243:00PMBusiness WireJohnson & Johnson to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceNYSE:JNJJohnson and Johnson
07/22/202410:59AMBusiness WireLawyers for Ovarian Cancer Victims Urge NO Vote on J&J’s Latest Bankruptcy PlanNYSE:JNJJohnson and Johnson
07/22/20247:00AMPR Newswire (US)Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depressionNYSE:JNJJohnson and Johnson
07/17/20247:14AMEdgar (US Regulatory)Form 8-K - Current reportNYSE:JNJJohnson and Johnson
07/17/20245:30AMIH Market NewsTech-Led Decline in U.S. Index Futures Pre-Market, Oil Prices Steady After U.S. Inventory DropNYSE:JNJJohnson and Johnson
07/17/20245:28AMIH Market NewsSpirit Airlines Cuts Revenue Forecast, J.B. Hunt Disappoints Analysts’ Estimates, and More Earnings UpdatesNYSE:JNJJohnson and Johnson
07/17/20245:25AMBusiness WireJohnson & Johnson Announces Quarterly Dividend for Third Quarter 2024NYSE:JNJJohnson and Johnson
07/17/20245:20AMBusiness WireJohnson & Johnson reports Q2 2024 resultsNYSE:JNJJohnson and Johnson
07/11/20246:30AMBusiness WireJohnson & Johnson Strengthens Pipeline to Lead in Atopic Dermatitis With the Completion of the Acquisition of Yellow Jersey Therapeutics, Gaining Ownership of NM26NYSE:JNJJohnson and Johnson
07/09/20244:48PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:JNJJohnson and Johnson
07/03/20247:00AMPR Newswire (Canada)Health Canada Authorizes RYBREVANT® (amivantamab) in Combination with Carboplatin and Pemetrexed as the Only Targeted First-line Treatment Approved for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion MutationsNYSE:JNJJohnson and Johnson
07/03/20247:00AMPR Newswire (Canada)Santé Canada autorise le traitement par RYBREVANT® (amivantamab) en association avec le carboplatine et le pemetrexed comme seul traitement de première intention ciblé approuvé pour les patients atteints d'un cancer du poumon non à petites cellules pNYSE:JNJJohnson and Johnson
07/02/20246:30AMPR Newswire (US)CARVYKTI® (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 studyNYSE:JNJJohnson and Johnson
06/28/202410:30AMPR Newswire (US)Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patientsNYSE:JNJJohnson and Johnson
06/27/20245:46PMBusiness WireLawyers for Johnson & Johnson’s Ovarian Cancer Victims React to SCOTUS Decision in PurdueNYSE:JNJJohnson and Johnson
06/21/20246:30AMBusiness WireJohnson & Johnson Completes Acquisition of Proteologix, Inc.NYSE:JNJJohnson and Johnson
06/20/20243:30PMPR Newswire (US)Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn's diseaseNYSE:JNJJohnson and Johnson
06/20/202412:07PMBusiness WireMore than 60 Law Firms Oppose J&J Prepack Bankruptcy SchemeNYSE:JNJJohnson and Johnson
06/20/20247:00AMPR Newswire (US)TREMFYA® (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both subcutaneous and intravenous inductionNYSE:JNJJohnson and Johnson
06/20/20245:55AMIH Market NewsTrump Media Resells Stocks and Warrants; KB Home Exceeds Q2 Expectations, and More NewsNYSE:JNJJohnson and Johnson
06/17/20244:55PMBusiness WireBeasley Allen and Levin Papantonio: Leading Law Firms Seek Protection for Future Victims of Johnson & Johnson Talc ProductsNYSE:JNJJohnson and Johnson
06/17/20247:00AMPR Newswire (US)Subcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancerNYSE:JNJJohnson and Johnson
 Showing the most relevant articles for your search:NYSE:JNJ

Your Recent History

USOTC
IDVV
International Endeavors (PK)
USOTC
AABB
Asia Broadband (PK)
AMEX
FOXO
FOXO Technologies
NASDAQ
AMRN
Amarin
NYSE
AMC
AMC Entertainment
USOTC
AHRO
Authentic (CE)
USOTC
VPLM
Voip Pal Com (QB)
USOTC
SPZI
Spooz (PK)
NASDAQ
MULN
Mullen Automotive
NASDAQ
NVDA
NVIDIA
NYSE
GME
GameStop
USOTC
CLNV
Clean Vision (QB)
USOTC
NSAV
Net Savings Link (PK)
USOTC
SHMP
NaturalShrimp (QB)
NASDAQ
AMD
Advanced Micro Devices
USOTC
SAPX
Seven Arts Entertainment (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved